Oral: Clinical Applications

These abstracts are expected to deal with applications of pharmacometrics whose aim is to improve individual patient treatment. They may include studies that have identified covariates that can be applied to calculate the dose, or even better, if the application was able to take patient response (concentration, biomarker) and further improve the individual dose. They can include simulation studies that explore how to improve patient treatment by dose individualization. The abstract must indicate an algorithm demonstrating how an individual patient dose is calculated.

Model-based analysis of the relationship between pembrolizumab exposure and efficacy in patients with melanoma and NSCLC: across indication comparison

Thursday 16 October, 2025

Objectives: To quantify the relationship between exposure to the Programmed Cell Death 1 (PD-1) inhibitor pembrolizumab in serum (AUC over…

The Impact of Model Selection for Personalised Dosing

Thursday 16 October, 2025

Objectives: Model based personalised dosing (MBPD) is a form of individualised therapy where patient specific pharmacokinetic (PK) or pharmacodynamic parameters are…

Prospective evaluation of Therapeutic Drug Monitoring of endoxifen: feasibility of observational and randomized trials.

Thursday 16 October, 2025

Objectives Tamoxifen is an anti-estrogenic drug that has been used to treat estrogen receptor (ER)-positive breast cancer for decades. Five…

Translational systems pharmacology for acquisition of knowledge and prediction of drug pharmacokinetics across patient populations

Thursday 16 October, 2025

Objectives: Identify and translate (patho-) physiological and drug-specific knowledge across distinct patient populations for the subsequent prediction of drug PK in…

Exposure-response (E-R)-based product-profile (PP)-driven clinical utility index (CUI) to support phase III dose selection in oncology

Thursday 16 October, 2025

Introduction/Objectives:Benefit-risk assessment of a therapeutic agent can support decision-making in both drug development and regulatory evaluation. The traditional way of…

Bayesian forecasting utilizing bleeding information to support dose individualization of factor VIII

Thursday 16 October, 2025

Objectives:Model-based PK-guided dose individualization of factor VIII (FVIII) replacement therapy has been increasingly encouraged [1,2]. Yet, mounting evidence shows large…

A mixed-effect modeling framework to personalize treatment of low-grade glioma patients

Thursday 16 October, 2025

Objective: We aim to develop a mixed-effect modeling framework to predict the effect and the duration of temozolomide (TMZ) treatment…

Personalizing hemodialysis (HD) treatment in pediatric patients with end-stage renal disease (ESRD) – application and integration of quantitative pharmacology with machine learning

Thursday 16 October, 2025

Objectives: End-stage renal disease (ESRD) is associated with high morbidity and mortality. A large proportion of patients receive intermittent hemodialysis…

Model-based development of the secukinumab dosing regimen for the treatment of moderate-to-severe chronic plaque psoriasis

Thursday 16 October, 2025

Objectives: In order to identify optimized dosing regimens for phase 3, this model-based analysis integrated data from several phase 2 studies…

Population K-PD joint modeling of tumor size and CA 125 kinetics after chemotherapy in relapsed ovarian cancer (ROC) patients

Thursday 16 October, 2025

Objectives: Ovarian cancer remains the leading cause of gynecologic cancer deaths. CA125 is used as a serum marker of epithelial…